Biodexa Pharmaceuticals Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BDRX research report →
Companywww.biodexapharma.com
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma.
- CEO
- Stephen Anthony Stamp
- IPO
- 2015
- Employees
- 13
- HQ
- Cardiff, GB
Price Chart
Valuation
- Market Cap
- $521.72K
- P/E
- -0.08
- P/S
- 0.00
- P/B
- 0.05
- EV/EBITDA
- 0.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -55.81%
- ROIC
- -72.30%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-6,244,097 · -8.99%
- EPS
- $-60.00 · 99.99%
- Op Income
- $-8,268,734
- FCF YoY
- 58.60%
Performance & Tape
- 52W High
- $96.50
- 52W Low
- $2.86
- 50D MA
- $3.62
- 200D MA
- $18.38
- Beta
- 1.16
- Avg Volume
- 761.10K
Get TickerSpark's AI analysis on BDRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Parker Stephen Barry | other | 576 |
| Mar 18, 26 | Merchant Ann Louise | other | 288 |
| Mar 18, 26 | Stamp Stephen Anthony | other | 859 |
| Mar 18, 26 | Stamp Stephen Anthony | other | 1,500 |
| Mar 18, 26 | Stamp Stephen Anthony | other | 25,000 |
| Mar 18, 26 | Stamp Stephen Anthony | other | 15,000 |
| Mar 18, 26 | de Vries Simon | other | 288 |
| Mar 18, 26 | Powell Fiona Mary | other | 286 |
| Mar 18, 26 | Powell Fiona Mary | other | 7,500 |
| Mar 18, 26 | Powell Fiona Mary | other | 8,750 |
Our BDRX Coverage
We haven't published any research on BDRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BDRX Report →